On May 6, 2026, the FDA approved Tessie (tasipimidine oral solution), sponsored by Orion Corporation, for the treatment of noise aversion and separation anxiety in dogs. It is the first drug the agency has approved for both conditions in a single product — a meaningful distinction, because the two fear-based behaviors frequently occur together, and until now they were treated with different drugs approved for different indications.

The approval does not change the fundamentals of canine behavioral medicine: medication is most useful as an adjunct to behavior modification, not a replacement for it. What it does is give veterinarians and owners a single, labeled, situational option that targets the shared physiology underneath both conditions. This article explains what tasipimidine is, how it is used, and how it compares to the options owners are likely already weighing.

What tasipimidine is, and the mechanism it shares

Tasipimidine is an alpha-2 adrenoceptor agonist. It works by activating alpha-2 receptors in the brain, which turns down the heightened sympathetic — fight-or-flight — nervous system activity that drives the panic of a thunderstorm or a departure. Mechanistically, it belongs to the same drug class as dexmedetomidine, the active ingredient in Sileo, the oromucosal gel approved for canine noise aversion. Tasipimidine is a distinct molecule, used here at a low oral dose for an anxiolytic rather than a sedative-anesthetic effect.

The key practical property is that it is a situational drug: given before a predictable trigger, rather than taken every day the way a chronic SSRI or tricyclic antidepressant would be. That makes it well suited to events with a clear onset — fireworks, a planned departure, a veterinary visit for an anxious patient — and a poor fit for round-the-clock generalized anxiety, which is a different treatment conversation.

What the approval covers

The FDA evaluated two controlled field studies. For noise aversion, a study in 160 client-owned dogs found tasipimidine safe and effective at 30 mcg/kg, given as needed up to three times during a noise event with at least three hours between doses. For separation anxiety, a multi-site study followed 224 dogs over eight weeks. In both cases the drug was tested in real homes against real triggers, not in a laboratory.

The most common adverse reactions reported in the treated group were vomiting and lethargy. The product is prescription-only, because diagnosing and treating noise aversion and separation anxiety — and ruling out medical contributors to the behavior — requires veterinary input.

How it is dosed and given

Tessie is given orally about one hour before the start of a predictable trigger — a noise event such as fireworks, or before leaving the dog alone. The labeled dose is weight-based (30 mcg/kg), drawn from the bottle with the supplied oral syringe. It can be given up to three times in 24 hours, with at least three hours between doses.

Two administration details matter and are easy to get wrong:

• Give it on an empty stomach. Food delays absorption, so the FDA advises waiting at least one hour after feeding before dosing. A very small treat to ensure the dog swallows the solution is acceptable; a full meal is not.
• Observe the dog for two hours after the first dose. Drowsiness, uncoordinated movement, or an abnormally slow response when called can signal that the dose is too high, and the manufacturer specifically flags an inability to walk normally or stand two hours after dosing as a red flag.

Where it fits against the existing options

Most owners considering Tessie are already weighing it against drugs they have heard about or used. The decision is usually between a situational medication and a daily one, and between an alpha-2 agonist and other mechanisms:

A few patterns fall out of this. First, the situational alpha-2 agonists — Tessie and Sileo — are cousins: both dampen sympathetic arousal, both are taken before a trigger, both wear off. Tessie's advantage is the labeled separation-anxiety indication and an oral solution; Sileo's is an established track record for noise aversion specifically and a faster oromucosal route. Second, trazodone and clonidine are widely used off-label and effective for many dogs, but neither carries an FDA-approved canine anxiety indication, which matters to owners and prescribers who weigh labeled evidence heavily. Third, daily SSRIs and TCAs (fluoxetine, clomipramine) are the right tools for chronic, pervasive anxiety that needs a steady baseline — they are not interchangeable with a situational drug like tasipimidine, and the two approaches are often combined.

Who is not an ideal candidate, and what to watch

Because tasipimidine is an alpha-2 agonist, the safety considerations of the class apply even at an anxiolytic dose: sedation, a drop in heart rate and blood pressure, and, at higher exposure, incoordination. The labeling cautions against use in dogs with moderate or severe systemic disease — specifically significant renal, liver, or cardiovascular disease — and in a dog that is already sedated from a previous dose. These are not arbitrary exclusions: a patient with ASA grade III or worse illness is exactly the patient in whom a drop in heart rate and blood pressure is poorly tolerated. The alpha-2 class also has a specific reversal agent (atipamezole) that prescribers know how to use if a dog is over-sedated.

One interaction matters in real-world use. Many dogs with separation anxiety or generalized anxiety are already on a daily SSRI or tricyclic — most often fluoxetine or clomipramine. The product labeling provides for concurrent use, but recommends reducing the tasipimidine dose to 20 mcg/kg (from the usual 30 mcg/kg) when it is given alongside fluoxetine or clomipramine, with a monitored test dose. So the situational alpha-2 agonist and the daily antidepressant can be combined, but not at the full dose without veterinary adjustment.

Two handler-safety points round out the picture. Keep the filled oral syringe and the bottle out of the reach of children and avoid skin and oral contact: human exposure to an alpha-2 agonist can cause drowsiness, slowed breathing, and lowered heart rate and blood pressure. And because tasipimidine adds cardiovascular depression, a dog that later needs general anesthesia may need a reduced propofol and isoflurane requirement — something to flag to any vet handling a sedation or surgery on a treated dog.

Two practical limitations are worth setting expectations around. The roughly one-hour onset is fine for fireworks with a known start time but can be too slow for an unpredictable summer thunderstorm that is already overhead — a dog that needs help in minutes, not an hour, may be better served by a faster-acting option. And because the drug reduces panic rather than teaching coping skills, it works best when it is paired with a behavior-modification plan (desensitization and counterconditioning to the trigger, structured departure practice) rather than used alone.

What to ask your veterinarian

If you are considering Tessie for a dog with noise aversion or separation anxiety, the conversation is less about whether the drug works — the studies support that — and more about fit:

• Is the dog's anxiety tied to a predictable trigger (good fit) or is it constant and generalized (a daily medication may be more appropriate)?
• Does the dog have any cardiovascular or respiratory disease that makes an alpha-2 agonist a less ideal choice?
• How should the first dose be timed and observed, and what counts as "too sedated"?
• What behavior-modification plan should run alongside the medication?
• If the dog is already on a daily SSRI or TCA, is adding a situational alpha-2 agonist appropriate?

Tessie fills a genuine gap — a single labeled drug for two conditions that usually travel together — but it is one tool in a behavioral plan, not a substitute for one. The owners who do best with it are the ones using the medication to make the training work.

Sources

• FDA, "FDA Approves First Drug to Treat Noise Aversion and Separation Anxiety in Dogs" (May 6, 2026), https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-treat-noise-aversion-and-separation-anxiety-dogs
• Tessie (tasipimidine oral solution) Freedom of Information Summary, NADA 141-627 (May 6, 2026), https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/18406
• AAHA, "FDA approves oral drug to manage both noise aversion and separation anxiety in dogs" (May 22, 2026), https://www.aaha.org/trends-magazine/publications/fda-approves-oral-drug-to-manage-both-noise-aversion-and-separation-anxiety-in-dogs/
• dvm360, "FDA approves first drug for both noise aversion and separation anxiety in dogs," https://www.dvm360.com/view/fda-approves-first-drug-for-both-noise-aversion-and-separation-anxiety-in-dogs
• Vet Candy, "FDA Approves Tessie (Tasipimidine): The First Medication for Both Dog Noise Aversion and Separation Anxiety," https://www.myvetcandy.com/news/2026/6/4/fda-approves-the-first-medication-proven-to-treat-both-dog-noise-aversion-and-separation-anxiety
• European Commission, Tessie (INN-tasipimidine) public assessment report — summary of product characteristics (contraindications, SSRI/TCA dose reduction, handler precautions), https://ec.europa.eu/health/documents/community-register/2023/20230830160281/anx_160281_en.pdf
• UK Veterinary Medicines Directorate, Tessie summary of product characteristics (anesthesia and interaction guidance), https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC_Documents/SPC_2146308.PDF